James J. Saller

1.0k total citations
25 papers, 275 citations indexed

About

James J. Saller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, James J. Saller has authored 25 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in James J. Saller's work include Neuroendocrine Tumor Research Advances (6 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). James J. Saller is often cited by papers focused on Neuroendocrine Tumor Research Advances (6 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). James J. Saller collaborates with scholars based in United States, China and Türkiye. James J. Saller's co-authors include Theresa A. Boyle, Jhanelle E. Gray, Hong Zheng, Tawee Tanvetyanon, Scott Antonia, Ben Creelan, Michael Shafique, Dung‐Tsa Chen, Andreas Saltos and Eric B. Haura and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

James J. Saller

24 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James J. Saller United States 8 142 119 75 47 46 25 275
D. Viñal Spain 10 166 1.2× 88 0.7× 90 1.2× 45 1.0× 33 0.7× 33 285
Fumiaki Shiratori Japan 10 98 0.7× 79 0.7× 56 0.7× 56 1.2× 47 1.0× 35 223
Ji‐Hye Oh South Korea 9 92 0.6× 91 0.8× 59 0.8× 26 0.6× 72 1.6× 14 220
Frank Ziemann Germany 8 113 0.8× 121 1.0× 57 0.8× 23 0.5× 58 1.3× 10 259
Kristen D. Felt United States 8 204 1.4× 111 0.9× 72 1.0× 71 1.5× 39 0.8× 23 306
Petia Mitchell United States 8 185 1.3× 194 1.6× 54 0.7× 65 1.4× 75 1.6× 13 380
Gonzalo Giornelli Argentina 5 110 0.8× 84 0.7× 36 0.5× 25 0.5× 52 1.1× 8 421
Elke Veltrup Germany 9 122 0.9× 95 0.8× 47 0.6× 31 0.7× 75 1.6× 22 255
Nathalie Rioux-Leclerc France 6 128 0.9× 84 0.7× 62 0.8× 95 2.0× 58 1.3× 9 255
Shingo Togano Japan 10 107 0.8× 124 1.0× 60 0.8× 50 1.1× 72 1.6× 27 256

Countries citing papers authored by James J. Saller

Since Specialization
Citations

This map shows the geographic impact of James J. Saller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Saller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Saller more than expected).

Fields of papers citing papers by James J. Saller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Saller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Saller. The network helps show where James J. Saller may publish in the future.

Co-authorship network of co-authors of James J. Saller

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Saller. A scholar is included among the top collaborators of James J. Saller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Saller. James J. Saller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations
2.
Lee, Kyubum, Mahmoud A. Abdalah, Theresa A. Boyle, et al.. (2023). Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI). npj Precision Oncology. 7(1). 68–68. 4 indexed citations
3.
Nasir, Aejaz, James J. Saller, Evita Henderson‐Jackson, et al.. (2023). p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors. Cancer Genomics & Proteomics. 20(6). 522–530. 1 indexed citations
4.
Saller, James J., et al.. (2023). An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms. Cancer Genomics & Proteomics. 20(2). 154–164. 2 indexed citations
5.
Saller, James J., et al.. (2022). Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin. Anticancer Research. 42(3). 1381–1396. 1 indexed citations
6.
Saller, James J., et al.. (2022). Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett’s Neoplasia. Cancer Genomics & Proteomics. 19(2). 145–150. 2 indexed citations
7.
Tunali, Ilke, Yan Tan, Jhanelle E. Gray, et al.. (2021). Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectrum. 5(4). 31 indexed citations
8.
Saller, James J., Kun Jiang, Yin Xiong, et al.. (2021). A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer. Digestive Diseases and Sciences. 67(2). 516–523. 6 indexed citations
9.
Saller, James J. & Theresa A. Boyle. (2021). Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine. 12(3). a037812–a037812. 28 indexed citations
10.
Lee, Kyubum, Mahmoud A. Abdalah, Theresa A. Boyle, et al.. (2021). Abstract PO-082: Automated tumor segmentation, grading, and analysis of tumor heterogeneity in preclinical models of lung adenocarcinoma. Clinical Cancer Research. 27(5_Supplement). PO–82. 1 indexed citations
11.
Kang, Yun Pyo, Aimee Falzone, Min Liu, et al.. (2020). PHGDH supports liver ceramide synthesis and sustains lipid homeostasis. SHILAP Revista de lepidopterología. 8(1). 18 indexed citations
12.
Saller, James J., Dahui Qin, Seth Felder, & Domenico Coppola. (2020). Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Clinical Colorectal Cancer. 19(2). 123–131. 2 indexed citations
13.
Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2020). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9567–9567. 12 indexed citations
14.
Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations
15.
Shahid, Mohd, James J. Saller, David Boulware, et al.. (2019). FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms. Pancreas. 48(10). 1307–1311. 6 indexed citations
16.
Saller, James J., Sameer Al Diffalha, David Boulware, et al.. (2019). CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett’s Esophagus. Digestive Diseases and Sciences. 65(7). 1992–1998. 5 indexed citations
17.
Saller, James J., Mohd Shahid, Mauro Cives, et al.. (2019). EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics & Proteomics. 16(5). 309–318. 4 indexed citations
18.
Saller, James J., et al.. (2018). Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. Journal of the National Comprehensive Cancer Network. 16(7). 797–800. 20 indexed citations
19.
Saller, James J., et al.. (2018). EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas. Cancer Genomics & Proteomics. 15(3). 201–205. 8 indexed citations
20.
Knepper, Todd C., James J. Saller, & Christine M. Walko. (2017). Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.. PubMed. 31(2). 138–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Viñal Breakdown of academic impact, for papers by Fumiaki Shiratori Breakdown of academic impact, for papers by Ji‐Hye Oh Breakdown of academic impact, for papers by Frank Ziemann Breakdown of academic impact, for papers by Kristen D. Felt Breakdown of academic impact, for papers by Petia Mitchell Breakdown of academic impact, for papers by Gonzalo Giornelli Breakdown of academic impact, for papers by Elke Veltrup Breakdown of academic impact, for papers by Nathalie Rioux-Leclerc Breakdown of academic impact, for papers by Shingo Togano
Rankless by CCL
2026